‘ATORM-C / Organoid Sciences - LARVOL DELTA

Organoid Science announced on March 16 that the Ministry of Food and Drug Safety has approved its IND (Investigational New Drug) application for a Phase 1 clinical trial of ‘ATORM-C’, an intestinal organoid therapy derived from autologous adult stem cells, targeting patients with Crohn’s disease accompanied by colonic ulcers. (The Asia Business Daily) - "A total of 9 to 18 patients are expected to participate in the trial, with safety and efficacy monitored for up to 24 weeks following administration."

New P1 trial • Crohn's disease